An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 in Combination With Oral BIBF 1120 in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2018
At a glance
- Drugs Nintedanib (Primary) ; Volasertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 22 Sep 2015 Results published in the Annals of Oncology.
- 06 Feb 2013 Planned end date changed from 1 Jan 2013 to 1 Feb 2013 as reported by ClinicalTrials.gov.
- 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.